The 4th Annual Novel Conjugate Summit presents the latest advancements and strategies in bioconjugate drug development, focusing on novel targeting, payloads, and therapeutic delivery systems.
Topics
- Discovery of Precision Antibody Drug Conjugates With SMARCA2/4 Dual Degrader Payloads
- Hormone-Peptide Conjugates as Next Generation Targeted Therapy
- Endosomal Escape Vehicle (EEV)-Conjugated Therapeutics for Duchenne Muscular Dystrophy
- Delivery of BET Protein Degrader via CEACAM6-Targeted ADC for Pancreatic Cancer
- Optimizing Bispecific ADCs for Tumor Specificity
- Pioneering Targeting Ligands for Groundbreaking Conjugates
- DACs: Combining Protein Degraders With Antibody Precision
- Highlighting Updates From the Clinical Landscape of Novel Conjugates
- Leveraging Peptide Drug Conjugates to Expand Oncology Options
- Technology for Degrader-Antibody Conjugates With mAb-like Pharmacokinetics
- Force™ Platform for TFR1-Mediated Therapeutic Delivery for Muscle Diseases
- Targeted 225Ac Therapy Using Small Molecule, Peptide & Antibody Vectors
- Challenges in Process Development for Antibody Radio Conjugates
- Optimizing PK Profiles for Novel Conjugated Drugs
- Bicycle Conjugates for Precision Targeting of Solid Tumors
- Leveraging Bi-Cygni Bispecific ADCs for Solid Tumor Selectivity
- Expanding Platform Technologies for Next Generation Conjugates
- Advancing Nucleotide-Based Therapeutics With Antibody-Oligonucleotide Conjugates
- Spotlighting High-Throughput Discovery of Bioconjugates
Who should Attend
- Biotechnology Innovators
- Oncology Drug Developers
- Pharmaceutical Scientists
- Clinical Researchers in Conjugated Therapies
- Bioconjugate Manufacturing Specialists
- Drug Development Researchers
- CMC Process Development Experts
- Experts in Targeted Therapeutic Delivery
- R&D Scientists in Antibody-Drug Conjugates
- Pharmaceutical Engineers
- Specialists in Protein Degradation Therapies
- Oncology and Immunology Researchers
- Drug Formulation Experts
- Academic Researchers in Bioconjugation
- Biopharma Leaders in Innovation
